JP2017537622A - がんを治療するための方法及び組成物 - Google Patents

がんを治療するための方法及び組成物 Download PDF

Info

Publication number
JP2017537622A
JP2017537622A JP2017529284A JP2017529284A JP2017537622A JP 2017537622 A JP2017537622 A JP 2017537622A JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017537622 A JP2017537622 A JP 2017537622A
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
acid sequence
domain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017529284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537622A5 (enExample
Inventor
セングプタ、サダク
サンパース、プラカーシュ
ピー． ユンハンス、リチャード
ピー． ユンハンス、リチャード
Original Assignee
ロジャー・ウィリアムズ・ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロジャー・ウィリアムズ・ホスピタル filed Critical ロジャー・ウィリアムズ・ホスピタル
Publication of JP2017537622A publication Critical patent/JP2017537622A/ja
Publication of JP2017537622A5 publication Critical patent/JP2017537622A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
JP2017529284A 2014-12-02 2015-12-01 がんを治療するための方法及び組成物 Pending JP2017537622A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086346P 2014-12-02 2014-12-02
US62/086,346 2014-12-02
PCT/US2015/063267 WO2016089916A1 (en) 2014-12-02 2015-12-01 Methods and compositons for treating cancer

Publications (2)

Publication Number Publication Date
JP2017537622A true JP2017537622A (ja) 2017-12-21
JP2017537622A5 JP2017537622A5 (enExample) 2019-01-10

Family

ID=56078487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529284A Pending JP2017537622A (ja) 2014-12-02 2015-12-01 がんを治療するための方法及び組成物

Country Status (18)

Country Link
US (2) US9650428B2 (enExample)
EP (1) EP3227317A4 (enExample)
JP (1) JP2017537622A (enExample)
KR (1) KR20180041087A (enExample)
CN (1) CN107709353A (enExample)
AR (1) AR102879A1 (enExample)
AU (1) AU2015355084A1 (enExample)
BR (1) BR112017011771A2 (enExample)
CA (1) CA2969714A1 (enExample)
EA (1) EA201791210A1 (enExample)
HK (1) HK1251862A1 (enExample)
IL (1) IL252610A0 (enExample)
MX (1) MX2017007272A (enExample)
PH (1) PH12017501031A1 (enExample)
SG (2) SG10202103475XA (enExample)
TW (1) TW201636425A (enExample)
UY (1) UY36418A (enExample)
WO (1) WO2016089916A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022084787A (ja) * 2015-06-19 2022-06-07 セバスチャン コボルド Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
JP2023539871A (ja) * 2020-08-26 2023-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グリア芽細胞腫を処置するための方法および組成物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
IN2015KN00329A (enExample) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
EP3227317A4 (en) 2014-12-02 2018-04-25 Roger Williams Hospital Methods and compositons for treating cancer
KR102011789B1 (ko) * 2015-08-05 2019-08-19 주식회사 셀랩메드 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
US20200095301A1 (en) * 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CA3078434A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
US20200289566A1 (en) * 2017-11-20 2020-09-17 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Compositions for improving car-t cell functionality and use thereof
AU2018393110B2 (en) 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
WO2019148006A1 (en) * 2018-01-26 2019-08-01 City Of Hope Chimeric antigen receptors and methods for reducing off target toxicity
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
CN110144326A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性抗肿瘤t细胞及其制备方法和应用
CN110157674A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CN108440674A (zh) * 2018-04-28 2018-08-24 杭州荣泽生物科技有限公司 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2021154543A2 (en) * 2020-01-31 2021-08-05 City Of Hope TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Rα2 POSITIVE MALIGNANCIES
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
US20230203108A1 (en) * 2020-05-28 2023-06-29 Chugai Seiyaku Kabushiki Kaisha Improved granzyme b variant
CN116390748A (zh) * 2020-09-11 2023-07-04 佐治亚大学研究基金会股份有限公司 用于预防和治疗流感感染的组合物及其使用方法
US12702710B2 (en) 2020-10-12 2026-08-11 Medicenna Therapeutics Inc. Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN113304267B (zh) * 2021-06-11 2022-03-15 河南大学 肺癌的治疗靶点及其应用
CN114014941B (zh) * 2022-01-10 2022-04-12 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164554A1 (en) * 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) * 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
MXPA04008408A (es) * 2002-03-01 2004-11-29 Squibb Bristol Myers Co Mamiferos no humanos, transgenicos, que expresan receptores de la tirosina cinasa activados constitutivamente.
US7709625B2 (en) * 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
CA2630334C (en) * 2005-11-16 2013-07-23 Universidad Nacional Autonoma De Mexico Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
CN101438158A (zh) * 2006-03-06 2009-05-20 阿穆尼克斯股份有限公司 遗传包和其应用
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
CA2735456C (en) * 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
CA2793753C (en) * 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
EP2931893A1 (en) * 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
IL305629A (en) * 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
EP3105333B1 (en) 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
EP3227317A4 (en) 2014-12-02 2018-04-25 Roger Williams Hospital Methods and compositons for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164554A1 (en) * 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLIN. CANCER RES., vol. 18, JPN6019039477, 2012, pages 5949 - 60, ISSN: 0004341817 *
FRONTIERS IN ONCOLOGY, vol. Vol.3, Article.322, JPN6019039472, 2013, pages 1 - 8, ISSN: 0004341816 *
GENE THERAPY, 2010, 17, P.389-399, JPN6020034004, ISSN: 0004341819 *
J CLIN INVEST., 2009, 119(7), P.1952-1963, JPN6020034007, ISSN: 0004341820 *
PLOS ONE, 2013, VOLUME 8, ISSUE 1, E51805, JPN6020034002, ISSN: 0004341818 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022084787A (ja) * 2015-06-19 2022-06-07 セバスチャン コボルド Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
JP7460675B2 (ja) 2015-06-19 2024-04-02 セバスチャン コボルド Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
US12570718B2 (en) 2015-06-19 2026-03-10 Sebastian Kobold PD-1-CD28 fusion proteins and their use in medicine
JP2023539871A (ja) * 2020-08-26 2023-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グリア芽細胞腫を処置するための方法および組成物
JP2023539870A (ja) * 2020-08-26 2023-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グリア芽細胞腫を処置するための方法および組成物

Also Published As

Publication number Publication date
MX2017007272A (es) 2018-06-06
SG11201704519YA (en) 2017-07-28
HK1251862A1 (zh) 2019-04-26
TW201636425A (zh) 2016-10-16
US20160151490A1 (en) 2016-06-02
BR112017011771A2 (pt) 2018-07-10
AU2015355084A1 (en) 2017-06-29
PH12017501031A1 (en) 2017-11-27
SG10202103475XA (en) 2021-05-28
KR20180041087A (ko) 2018-04-23
UY36418A (es) 2016-06-30
EA201791210A1 (ru) 2017-11-30
CN107709353A (zh) 2018-02-16
AR102879A1 (es) 2017-03-29
EP3227317A4 (en) 2018-04-25
US9650428B2 (en) 2017-05-16
WO2016089916A1 (en) 2016-06-09
EP3227317A1 (en) 2017-10-11
IL252610A0 (en) 2017-07-31
US20180072789A1 (en) 2018-03-15
CA2969714A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
US9650428B2 (en) Methods and compositions for treating cancer
JP7082046B2 (ja) 受容体
CN107849112B (zh) 嵌合抗原受体(car)、组合物及其使用方法
EP3283526B1 (en) Chimeric protein
CN110352245A (zh) 可分泌变体免疫调节蛋白和工程化细胞疗法
CN113423726A (zh) 为过继细胞治疗提供靶向共刺激的受体
CN106535925A (zh) 基于car的免疫治疗
WO2019053420A1 (en) CELL
HK1243107A1 (en) Chimeric protein
JP2021506275A (ja) 細胞
TWI843716B (zh) hTERT特異性結合分子
US11701387B2 (en) Chimeric antigen receptor specific for BDCA2 antigen
JP7591772B2 (ja) 強化された合成ｔ細胞受容体及び抗原受容体
US20250108069A1 (en) Chimeric adaptor polypeptides
JP2023511443A (ja) 普遍的免疫受容体を発現する操作された細胞の活性の量的制御
CA3215822A1 (en) Chimeric antigen receptor (car)-t cells
CN115279389A (zh) 新型显性负性Fas多肽、包含其的细胞及其用途
JP7054181B2 (ja) キメラ抗原受容体
WO2024011335A1 (zh) 经修饰的免疫细胞

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200908